Physician profile

James Mcgrory

Orthopaedic Surgery · Columbus, GA

NPI 1578506556

$1,815.93

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$1,103.23
Food and Beverage$356.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Globus Medical, INC. $935.48 2023 Monument, Excelsiusgps Robotic Navigation System, Sable
Stryker Corporation $546.84 2019-2024 Mako
Eisai INC. $116.95 2021
Choice Spine, LLC $93.78 2019
Djo, LLC $41.87 2020-2024 Cmf
Cgg Medical INC $37.04 2021
Avanos Medical $17.98 2023 Trivisc Sodium Hyaluronate
Depuy Synthes Sales INC. $14.04 2021
Next Science LLC $11.95 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Mcgrory

$1,815.93

in general payments reported 2019-2025

Years
2019-2024
Top company
Globus Medical, INC.

https://glasscript.com/doctor/721657/james-mcgrory

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.